Inventor · disambiguated record
Eileen Mary Seward
Also filed as: SEWARD EILEEN M · SEWARD EILEEN MARY · SEWARD Eileen
44 granted patents·6 pending applications·634 citations·filing 1992–2024
98Inventor score
Top patents by PatentIndex Score
50 records- 0195US11566003B2Isoquinolines as inhibitors of HPK1GENENTECH INC·Filed 2020·Granted Jan 31, 2023·4 cites·31 claims
- 0294US6172077B1Spiro-azacyclic derivatives and their use as therapeutic agentsMERCK SHARP & DOHME·Filed 1998·Granted Jan 9, 2001·149 cites·15 claims
- 0393US11820751B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2022·Granted Nov 21, 2023·3 cites·6 claims
- 0491US5496833APiperidine tachykinin receptor antagonistsMERCK SHARP & DOHME·Filed 1995·Granted Mar 5, 1996·73 cites·12 claims
- 0590US10407424B2Naphthyridines as inhibitors of HPK1GENENTECH INC·Filed 2018·Granted Sep 10, 2019·5 cites·72 claims
- 0689US5242930AAzabicyclic compounds, pharmaceutical compositions containing them and their use in therapyMERCK SHARP & DOHME·Filed 1992·Granted Sep 7, 1993·73 cites·11 claims
- 0788US7638629B2Piperidines and related compounds for treatment of alzheimer's diseaseMERCK SHARP & DOHME·Filed 2005·Granted Dec 29, 2009·13 cites·8 claims
- 0886US9890152B2Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutantsGENENTECH INC·Filed 2015·Granted Feb 13, 2018·7 cites·29 claims
- 0986US5952315AUse of NK-1 receptor antagonists for treating bipolar disordersMERCK SHARP & DOHME·Filed 1997·Granted Sep 14, 1999·34 cites·5 claims
- 1085US8394796B2Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of useCASTANEDO GEORGETTE·Filed 2012·Granted Mar 12, 2013·8 cites·20 claims
- 1184US12473269B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Nov 18, 2025·0 cites·12 claims
- 1284US9951064B2Azaindazole compounds as inhibitors of T790M containing EGFR mutantsGENENTECH INC·Filed 2016·Granted Apr 24, 2018·5 cites·15 claims
- 1383US12358884B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Jul 15, 2025·0 cites·20 claims
- 1483US8173650B2Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of useCASTANEDO GEORGETTE·Filed 2010·Granted May 8, 2012·7 cites·21 claims
- 1582US12351567B2Urolithin derivatives and methods of use thereofVANDRIA SA·Filed 2023·Granted Jul 8, 2025·0 cites·19 claims
- 1681US11034692B1Naphthyridines as inhibitors of HPK1GENENTECH INC·Filed 2019·Granted Jun 15, 2021·1 cites·20 claims
- 1781US8158625B2Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of useCASTANEDO GEORGETTE·Filed 2010·Granted Apr 17, 2012·6 cites·7 claims
- 1881US5612337ASubstituted morpholine derivatives and their use as therapeutic agentsMERCK SHARP & DOHME·Filed 1994·Granted Mar 18, 1997·46 cites·24 claims
- 1978US8653089B2Heterocyclic compounds and methods of useHEALD ROBERT·Filed 2012·Granted Feb 18, 2014·5 cites·3 claims
- 2077US6489343B2Tetrahydropyran derivatives and their use as therapeutic agentsMERCK SHARP & DOHME·Filed 2001·Granted Dec 3, 2002·9 cites·10 claims
- 2175US2024368170A1Cinnoline compounds and uses thereofGENENTECH INC·Filed 2024·Application pending·0 cites
- 2273US6458830B1Tetrahydropyran derivatives and their use as therapeutic agentsMERCK SHARP & DOHME·Filed 2000·Granted Oct 1, 2002·7 cites·22 claims
- 2373US5929054AUse of NK-1 receptor antagonists for treating sexual dysfunctionsMERCK SHARP·Filed 1997·Granted Jul 27, 1999·41 cites·3 claims
- 2472US12098148B2Therapeutic compoundsC4X DISCOVERY LTD·Filed 2019·Granted Sep 24, 2024·2 cites·32 claims
- 2567US10952995B2Azaindoles as inhibitors of HPK1GENENTECH INC·Filed 2019·Granted Mar 23, 2021·0 cites·32 claims
- 2667US5728695ASpiroketal derivatives, compositions containing them and their use as therapeutic agentsMERCK SHARP & DOHME·Filed 1995·Granted Mar 17, 1998·26 cites·28 claims
- 2766US6046195ASpiro-azacyclic derivatives, their preparation and their use as tachykinin antagonistsMERCK SHARP & DOHME·Filed 1997·Granted Apr 4, 2000·26 cites·20 claims
- 2865US6114315AUse of NK-1 receptor antagonists for treating major depressive disorders with anxietyMERCK SHARP & DOHME·Filed 1998·Granted Sep 5, 2000·26 cites·4 claims
- 2965US2025084075A1Therapeutic compoundsC4X DISCOVERY LTD·Filed 2024·Application pending·0 cites
- 3064US11944606B2Azaindoles as inhibitors of HPK1GENENTECH INC·Filed 2021·Granted Apr 2, 2024·0 cites·20 claims
- 3162US7101892B2Sulfone derivatives as 5-HT7 receptor ligandsMERCK SHARP & DOHME·Filed 2004·Granted Sep 5, 2006·2 cites·11 claims
- 3262US2022073520A1Cinnoline compounds and uses thereofGENENTECH INC·Filed 2021·Application pending·0 cites
- 3360US9090628B2Benzoxazepin compounds selective for PI3K P110 delta and methods of useHEFFRON TIMOTHY·Filed 2012·Granted Jul 28, 2015·1 cites·6 claims
- 3456US6071927ASpiro-piperidine derivatives and their use as therapeutic agentsMERCK SHARP & DOHME·Filed 1997·Granted Jun 6, 2000·13 cites·24 claims
- 3554US12208088B2Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereofGENENTECH INC·Filed 2021·Granted Jan 28, 2025·0 cites·29 claims
- 3654US2018282282A1Isoquinolines as inhibitors of hpk1GENENTECH INC·Filed 2018·Application pending·0 cites
- 3753US12378249B2Isoquinoline compounds and uses thereofGENENTECH INC·Filed 2021·Granted Aug 5, 2025·0 cites·25 claims
- 3853US12297210B2Naphthyridine compounds and uses thereofGENENTECH INC·Filed 2021·Granted May 13, 2025·0 cites·15 claims
- 3951US2023159511A1Tetrahydroisoquinoline compounds as nrf2 activatorsC4X DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 4050US2023167084A1Tetrahydroisoquinoline compounds as nrf2 activatorsC4X DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 4148US5925627AUse of NK-1 receptor antagonists for treating movement disordersMERCK SHARP & DOHME·Filed 1997·Granted Jul 20, 1999·7 cites·11 claims
- 4247US5561130AAzacyclic compoundsMERCK SHARP & DOHME·Filed 1993·Granted Oct 1, 1996·6 cites·14 claims
- 4346US5665883AAralkoxy and aralkylthio substituted azacyclic compounds as tachykinin antagonistsMERCK SHARP & DOHME·Filed 1995·Granted Sep 9, 1997·6 cites·10 claims
- 4443US6271230B1Use of NK-1 receptor antagonists for treating cognitive disordersMERCK SHARP & DOHME·Filed 1999·Granted Aug 7, 2001·6 cites·5 claims
- 4543US5877316AMorpholine derivatives, compositions containing them and their use as therapeutic agentsMERCK SHARP & DOHME·Filed 1996·Granted Mar 2, 1999·6 cites·21 claims
- 4641US5919781AUse of NK-1 receptor antogonists for treating substance use disordersMERCK SHARP & DOHME·Filed 1997·Granted Jul 6, 1999·5 cites·6 claims
- 4739US5747491AMorpholine derivatives and their use as antagonists of tachikininsMERCK SHARP & DOHME·Filed 1995·Granted May 5, 1998·3 cites·7 claims
- 4838US6087348AUse of NK-1 receptor antagonists for treating stress disordersMERCK SHARP & DOHME·Filed 1999·Granted Jul 11, 2000·3 cites·15 claims
- 4937US8389547B2Piperidines and related compounds for the treatment of Alzheimer's diseaseGARCIA YUDITH·Filed 2007·Granted Mar 5, 2013·0 cites·11 claims
- 5031US6096729AUse of NK-1 receptor antagonists for treating amnestic disordersMERCK SHARP & DOHME·Filed 1997·Granted Aug 1, 2000·0 cites·5 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →